Amicus Therapeutics recently submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational oral medicine migalastat for treatment of patients 16 years and older with Fabry disease who have so-called “amenable” mutations. The NDA seeks migalastat’s approval in the U.S. as an alternative to intravenous enzyme…
News
Recent Posts
- Long-term therapy stabilizes eye health in Fabry disease, study finds
- Staying active can be challenging with Fabry disease and chronic pain
- Early kidney signs may emerge before symptoms in Fabry disease
- New GLA gene mutation tied to heart-focused Fabry disease
- Heart changes may reveal late-onset Fabry disease, case report finds